Spinal Muscular Atrophy clinical trials

Explore recruiting spinal muscular atrophy clinical trials.

Recruiting spinal muscular atrophy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Spinal Muscular Atrophy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label Study of Risdiplam in Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy

Poland, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101

Belgium, France, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, Open-label Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants with Spinal Muscular Atrophy

Norway, Italy, Belgium, Germany, Poland, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Long-term Follow-up of Patients with Spinal Muscular Atrophy Treated with OAV101 IT or OAV101 IV in Clinical Trials

Netherlands, Belgium, France, Denmark, Spain, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Ambulatory and Non-Ambulatory Participants with Spinal Muscular Atrophy with Open-Label Extension (RESILIENT)

Italy, Poland, Spain, Germany, Belgium, Czechia +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open Label, Single Cohort Study to Assess the Pharmacokinetic Profile of Nusinersen (BIIB058) Administered via the ThecaFlex DRx™ System (PIERRE-PK)

Poland, France, Spain, Germany, Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

Spinal Muscular Atrophy trials by city

Spinal Muscular Atrophy in Toronto Spinal Muscular Atrophy in Vancouver Spinal Muscular Atrophy in Montreal Spinal Muscular Atrophy in Calgary Spinal Muscular Atrophy in Edmonton Spinal Muscular Atrophy in Ottawa Spinal Muscular Atrophy in Winnipeg Spinal Muscular Atrophy in Quebec City Spinal Muscular Atrophy in Hamilton Spinal Muscular Atrophy in Kitchener Spinal Muscular Atrophy in London Spinal Muscular Atrophy in Halifax Spinal Muscular Atrophy in New York Spinal Muscular Atrophy in Los Angeles Spinal Muscular Atrophy in Chicago Spinal Muscular Atrophy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease